{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:16:13Z","timestamp":1779297373736,"version":"3.51.4"},"reference-count":27,"publisher":"Termedia Sp. z.o.o.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"published-print":{"date-parts":[[2020,12,23]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Juvenile idiopathic arthritis is the most common rheumatic disease in childhood. Biologic agents have changed the course of juvenile idiopathic arthritis. However, there are concerns regarding the occurrence of serious adverse events in patients receiving biologic agents. The aim of this study was to evaluate adverse events in children with juvenile idiopathic arthritis receiving biologic agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>This retrospective study includes juvenile idiopathic arthritis patients receiving biologic agents. Demographic features and adverse events during biologic agents were collected from medical files. Adverse events that either resulted in death, were life-threatening, required inpatient hospitalization, or resulted in persistent or significant disability\/incapacity were considered as serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 162 juvenile idiopathic arthritis patients (55.6% female) receiving biologic agents were enrolled: 101 (62.3%) patients treated with etanercept, 27 (16.7) with tocilizumab, 14 (8.6%) with adalimumab, 15 (9.2%) with anti-interleukin 1 agents (13 canakinumab, 2 anakinra), and 5 (3.1%) with infli\u00adximab. 75.9% of the patients received concomitantly disease-modifying anti-rheumatic drugs, and 20.4% received disease-modifying anti-rheumatic drugs plus corticosteroid. The mean age at initiation of the biologic agent was 10.5 \u00b14.3 years. The mean age at the study enrolment was 12.1 \u00b14.5 years. The mean follow-up duration was 19.7 \u00b12.1 months. The most frequent adverse event was upper respiratory tract infections (54.3%) followed by urinary tract infections (21%). Anaphylaxis occurred in 3 patients (1.9%): 2 with tocilizumab and one with infliximab. Macrophage activation syndrome occurred in 1 patient (0.6%) receiving tocilizumab. Lung tuberculosis developed in 2 patients (1.2%) receiving canakinumab. The frequency of serious adverse events in total was 6.7%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While the most frequent adverse events during biologic agents was upper respiratory tract infections, the frequency of serious adverse events was 6.7%; therefore, juvenile idiopathic arthritis patients receiving biologic agents should be carefully evaluated for these adverse events in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.5114\/reum.2020.102001","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T20:38:10Z","timestamp":1609792690000},"page":"367-374","source":"Crossref","is-referenced-by-count":6,"title":["Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a\u00a0single center in Turkey"],"prefix":"10.5114","volume":"58","author":[{"given":"Sibel","family":"Balc\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lksen","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahir","family":"Serbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Do\u011fruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Ufuk Alt\u0131nta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia Miray","family":"K\u0131\u015fla Ekinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"ref-780805","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666180522085716"},{"key":"ref-780806","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1042453"},{"key":"ref-780807","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205372"},{"key":"ref-780808","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/B978-0-323-24145-8.00013-2","volume-title":"Textbook of Pediatric Rheumatology","author":"Ilowite NT","year":"2016","unstructured":"Ilowite NT, Laxer RM, Petty RE, Laxer RM, Lindsley CB, Wedderburn LR. (2016). Textbook of Pediatric Rheumatology. 161-175. Elsevier, Philadelphia."},{"key":"ref-780809","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2196"},{"key":"ref-780810","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4367-9"},{"key":"ref-780811","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2744-6"},{"key":"ref-780812","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150430"},{"key":"ref-780813","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22961"},{"key":"ref-780814","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747"},{"key":"ref-780815","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.08.003"},{"key":"ref-780816","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. (2004). International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 J Rheumatol. 31: 390-392.","journal-title":"J Rheumatol"},{"key":"ref-780817","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3982"},{"key":"ref-780818","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2013.34.3630"},{"key":"ref-780819","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu457"},{"key":"ref-780820","unstructured":". ().   http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"ref-780821","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv096"},{"key":"ref-780822","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.04.044"},{"key":"ref-780823","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0314"},{"key":"ref-780824","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.12.006"},{"key":"ref-780825","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex403"},{"key":"ref-780826","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044"},{"key":"ref-780827","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13114"},{"key":"ref-780828","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens EM","year":"2007","unstructured":"Behrens EM, Beukelman T, Paessler M, Cron RQ. (2007). Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis J Rheumatol. 34: 1133-1138.","journal-title":"J Rheumatol"},{"key":"ref-780829","doi-asserted-by":"publisher","DOI":"10.5152\/TurkPediatriArs.2015.3299"},{"key":"ref-780830","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1221875"},{"key":"ref-780831","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13129"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-131033-85942","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-131033-85942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:02:12Z","timestamp":1674806532000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Retrospective-analyzes-of-adverse-events-during-biologic-agents-in-children-with,131033,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"alternative-id":["131033"],"URL":"https:\/\/doi.org\/10.5114\/reum.2020.102001","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]}}}